Evidence suggests that psilocybin-assisted therapy for those who have not responded to standard interventions may be beneficial.
|Articles|March 1, 2003
- Volume 0 0
Infant Colic Does Not Have Lasting Effects on Mothers' Mental Health
Advertisement
Infant colic tends to resolve by 3 months of age and has little lasting effect on mothers? mental health, according to a recent article in the Archives of Pediatrics & Adolescent Medicine. Among 547 mother?baby pairs, 131 had colic at 6 weeks of age, but only 18 of these (13.7%) still had colic at 3 months. No significant changes in anxiety and depression scores from week 1 to 6 months postpartum were found when comparing mothers whose infants had colic versus those whose infants were not colicky.
Articles in this issue
over 23 years ago
Compounding a hydroxyurea liquidover 23 years ago
Does "HC" mean "hydrophilic cream"?over 23 years ago
A Vision for Pharmacy and How to Get There?Part 1over 23 years ago
Humira (adalimumab, D2E7)over 23 years ago
Drug Diversion Versus Pain Management?Part 1over 23 years ago
Pharmacy Pays Dearly After Misleading Courtover 23 years ago
Becoming a Culturally Competent Pharmacistover 23 years ago
Is There a Vaccine in Your Future?over 23 years ago
Growing Professionally with a MentorAdvertisement
Related to this article
Investigational antiamyloid monoclonal antibodies may offer a novel pathway to disease reversal.
Increasingly, pharmacists are leading the obesity management team.
A panel of cardiology pharmacists discussed the diagnostic red flags, evolving treatment landscape, and expanding pharmacist role central to identifying and managing ATTR-CM.
Weight-based norepinephrine dosing did not improve time to goal MAP, and median dose was similar compared with non–weight-based dosing in patients with septic shock.
The panelists emphasized that selecting a therapy is only one step toward improving outcomes for patients with heart failure.
Pharmacists can educate patients about staying up to date on immunizations and discuss fall prevention strategies.
Pharmacists describe their experiences using DEA certificates for controlled substance prescribing in different practice settings, as well as barriers and opportunities for future expansion.
Advertisement
Advertisement
Trending on Pharmacy Times
1
After 180 Years, Multiple Myeloma Gets a Definition of Cure
2
Psilocybin-Assisted Therapy for AUD: Emerging Evidence, Clinical and Cost Implications, and Treatment Gaps
3
Armored CAR T-Cell Therapy Produces Durable Complete Response in Pediatric Solid Tumors
4
Not So Rare After All: Pharmacists Weigh In on Diagnosing and Managing ATTR-CM
5